Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363012 · ClinicalTrials.gov registry record · NA
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00363012 is a NA study that has completed, run by University of Washington. The registered enrollment target is 56 participants.
The verdict
NCT00363012, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: This clinical trial is studying the immune response in patients who have undergone vaccine therapy for stage III or stage IV breast cancer that overexpresses HER2.
Interventions
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
- BIOLOGICAL HER-2/neu intracellular domain protein
- OTHER Sterile water placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363012
The ClinicalTrials.gov registry entry for NCT00363012 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT00363012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363012 about?
NCT00363012 is a clinical study titled "Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2". RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: This clinical trial is studying the immune response in patients who have undergone vaccine therapy for stage III o...
What is the current status of trial NCT00363012?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2006-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00363012?
The interventions under investigation include: biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), flow cytometry (OTHER), HER-2/neu intracellular domain protein (BIOLOGICAL), Sterile water placement (OTHER).
Who is sponsoring clinical trial NCT00363012?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.